Last Updated: September 24, 2026

Details for New Drug Application (NDA): 207202

✉ Email this page to a colleague

NDA 207202 describes ABILIFY MYCITE KIT, which is a drug marketed by Otsuka and is included in one NDA. There are twenty-seven patents protecting this drug. Additional details are available on the ABILIFY MYCITE KIT profile page.

The generic ingredient in ABILIFY MYCITE KIT is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

Summary for 207202

Tradename:	ABILIFY MYCITE KIT
Applicant:	Otsuka
Ingredient:	aripiprazole
Patents:	27

Medical Subject Heading (MeSH) Categories for 207202

Antipsychotic Agents

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	2MG
Approval Date:	Nov 13, 2017	TE:		RLD:	Yes
Patent:	10,441,194	Patent Expiration:	Jul 26, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	10,517,507	Patent Expiration:	Jun 13, 2032	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	11,229,378	Patent Expiration:	Jul 11, 2031	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 207202

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017	9,089,567	⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017	9,359,302	⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017	9,089,567	⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017	9,387,182	⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017	9,089,567	⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017	8,017,615	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.